Literature DB >> 17507627

Number of nevi and early-life ambient UV exposure are associated with BRAF-mutant melanoma.

Nancy E Thomas1, Sharon N Edmiston, Audrey Alexander, Robert C Millikan, Pamela A Groben, Honglin Hao, Dawn Tolbert, Marianne Berwick, Klaus Busam, Colin B Begg, Dianne Mattingly, David W Ollila, Chiu Kit Tse, Amanda Hummer, Julia Lee-Taylor, Kathleen Conway.   

Abstract

Malignant melanomas often contain BRAF or NRAS mutations, but the relationship of these mutations to ambient UV exposure in combination with phenotypic characteristics is unknown. In a population-based case series from North Carolina, 214 first primary invasive melanoma patients in the year 2000 were interviewed regarding their risk factors. Ambient solar UV exposures were estimated using residential histories and a satellite-based model. Cases were grouped on the basis of BRAF and NRAS somatic mutations, determined using single-strand conformation polymorphism analysis and radiolabeled DNA sequencing, and the risk profiles of these groups were compared. Mutually exclusive BRAF-mutant and NRAS-mutant cases occurred at frequencies of 43.0% and 13.6% with mean ages at diagnosis of 47.3 and 62.1 years, respectively. Tumors from patients with >14 back nevi were more likely to harbor either a BRAF mutation [age-adjusted odds ratio (OR), 3.2; 95% confidence interval (95% CI), 1.4-7.0] or an NRAS mutation (age-adjusted OR, 1.7; 95% CI, 0.6-4.8) compared with patients with 0 to 4 back nevi. However, BRAF-mutant and NRAS-mutant tumors were distinctive in that BRAF-mutant tumors were characteristic of patients with high early-life ambient UV exposure (adjusted OR, 2.6; 95% CI, 1.2-5.3). When ambient UV irradiance was analyzed by decadal age, high exposure at ages 0 to 20 years was associated with BRAF-mutant cases, whereas high exposure at ages 50 and 60 years was characteristic of NRAS-mutant cases. Our results suggest that although nevus propensity is important for the occurrence of both BRAF and NRAS-mutant melanomas, ambient UV irradiance influences risk differently based on the age of exposure. The association of BRAF mutations with early-life UV exposure provides evidence in support of childhood sun protection for melanoma prevention.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17507627     DOI: 10.1158/1055-9965.EPI-06-1038

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  71 in total

Review 1.  How sunlight causes melanoma.

Authors:  Lilit Garibyan; David E Fisher
Journal:  Curr Oncol Rep       Date:  2010-09       Impact factor: 5.075

2.  Factors associated with inconsistent sun protection in first-degree relatives of melanoma survivors.

Authors:  Elyse Shuk; Jack E Burkhalter; Carlos F Baguer; Susan M Holland; Alisa Pinkhasik; Mary Sue Brady; Daniel G Coit; Charlotte E Ariyan; Jennifer L Hay
Journal:  Qual Health Res       Date:  2012-07

3.  Prospective study of sunburn and sun behavior patterns during adolescence.

Authors:  Stephen W Dusza; Allan C Halpern; Jaya M Satagopan; Susan A Oliveria; Martin A Weinstock; Alon Scope; Marianne Berwick; Alan C Geller
Journal:  Pediatrics       Date:  2012-01-23       Impact factor: 7.124

4.  Utility of TERT Promoter Mutations for Cutaneous Primary Melanoma Diagnosis.

Authors:  Nancy E Thomas; Sharon N Edmiston; Yihsuan S Tsai; Joel S Parker; Paul B Googe; Klaus J Busam; Glynis A Scott; Daniel C Zedek; Eloise A Parrish; Honglin Hao; Nathaniel A Slater; Michelle V Pearlstein; Jill S Frank; Pei Fen Kuan; David W Ollila; Kathleen Conway
Journal:  Am J Dermatopathol       Date:  2019-04       Impact factor: 1.533

5.  IL2 Inducible T-cell Kinase, a Novel Therapeutic Target in Melanoma.

Authors:  Craig C Carson; Stergios J Moschos; Sharon N Edmiston; David B Darr; Nana Nikolaishvili-Feinberg; Pamela A Groben; Xin Zhou; Pei Fen Kuan; Shaily Pandey; Keefe T Chan; Jamie L Jordan; Honglin Hao; Jill S Frank; Dennis A Hopkinson; David C Gibbs; Virginia D Alldredge; Eloise Parrish; Sara C Hanna; Paula Berkowitz; David S Rubenstein; C Ryan Miller; James E Bear; David W Ollila; Norman E Sharpless; Kathleen Conway; Nancy E Thomas
Journal:  Clin Cancer Res       Date:  2015-05-01       Impact factor: 12.531

6.  Guidelines for biomarker testing in metastatic melanoma: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.

Authors:  S Martín-Algarra; M T Fernández-Figueras; J A López-Martín; A Santos-Briz; A Arance; M D Lozano; A Berrocal; J J Ríos-Martín; E Espinosa; J L Rodríguez-Peralto
Journal:  Clin Transl Oncol       Date:  2013-10-16       Impact factor: 3.405

Review 7.  BRAF and MEK gene rearrangements in melanoma: implications for targeted therapy.

Authors:  Pedro Madureira; Ramon Andrade de Mello
Journal:  Mol Diagn Ther       Date:  2014-06       Impact factor: 4.074

8.  Inherited Genetic Variants Associated with Melanoma BRAF/NRAS Subtypes.

Authors:  Nancy E Thomas; Sharon N Edmiston; Irene Orlow; Peter A Kanetsky; Li Luo; David C Gibbs; Eloise A Parrish; Honglin Hao; Klaus J Busam; Bruce K Armstrong; Anne Kricker; Anne E Cust; Hoda Anton-Culver; Stephen B Gruber; Richard P Gallagher; Roberto Zanetti; Stefano Rosso; Lidia Sacchetto; Terence Dwyer; David W Ollila; Colin B Begg; Marianne Berwick; Kathleen Conway
Journal:  J Invest Dermatol       Date:  2018-05-09       Impact factor: 8.551

9.  Melanoma molecular subtypes: unifying and paradoxical results.

Authors:  Nancy E Thomas; Peter A Kanetsky; Colin B Begg; Kathleen Conway; Marianne Berwick
Journal:  J Invest Dermatol       Date:  2010-01       Impact factor: 8.551

10.  Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.

Authors:  Kevin B Kim; Richard Kefford; Anna C Pavlick; Jeffrey R Infante; Antoni Ribas; Jeffrey A Sosman; Leslie A Fecher; Michael Millward; Grant A McArthur; Patrick Hwu; Rene Gonzalez; Patrick A Ott; Georgina V Long; Olivia S Gardner; Daniele Ouellet; Yanmei Xu; Douglas J DeMarini; Ngocdiep T Le; Kiran Patel; Karl D Lewis
Journal:  J Clin Oncol       Date:  2012-12-17       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.